Terms: = Lung cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Clinical Outcome
35 results:
1. A review on the role of HAND2-AS1 in cancer.
Ghafouri-Fard S; Hussen BM; Abdullah SR; Dadyar M; Taheri M; Kiani A
Clin Exp Med; 2023 Nov; 23(7):3179-3188. PubMed ID: 37204522
[TBL] [Abstract] [Full Text] [Related]
2. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
3. Relationship between the microRNAs and pi3k/AKT/mTOR axis: Focus on non-small cell lung cancer.
Lin Y; Zhang L; Ding X; Chen C; Meng M; Ke Y; Wang W
Pathol Res Pract; 2022 Nov; 239():154093. PubMed ID: 36183437
[TBL] [Abstract] [Full Text] [Related]
4. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract] [Full Text] [Related]
5. Identification and functional analysis of lncRNAs and mRNAs between tumorigenesis and metastasis in CRC.
Liu H; Tian Y; Li J; Zhang G; Liu Q; Yang M; Yue L; Cao Q; Zhang G; Cheng Y; Kong N; Fang L; Li S; Sun Q
Aging (Albany NY); 2021 Dec; 13(24):25859-25885. PubMed ID: 34954693
[TBL] [Abstract] [Full Text] [Related]
6. Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting pi3k/AKT signaling pathway.
Niu Z; Li Y; Xu Y; Jiang W; Tao R; Chen Y; Han Y
Bioengineered; 2021 Dec; 12(2):12193-12205. PubMed ID: 34783295
[TBL] [Abstract] [Full Text] [Related]
7. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Reissig TM; Sara L; Ting S; Reis H; Metzenmacher M; Eberhardt WEE; Zaun G; Herold T; Aigner C; Darwiche K; Stuschke M; Schildhaus HU; Schuler M; Wiesweg M
Lung Cancer; 2020 Nov; 149():10-16. PubMed ID: 32947221
[TBL] [Abstract] [Full Text] [Related]
8. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract] [Full Text] [Related]
9. clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
[TBL] [Abstract] [Full Text] [Related]
10. Carcinogen-induced tumors in SFN-transgenic mice harbor a characteristic mutation spectrum of human lung adenocarcinoma.
Kim Y; Shiba-Ishii A; Ramirez K; Muratani M; Sakamoto N; Iijima T; Noguchi M
Cancer Sci; 2019 Aug; 110(8):2431-2441. PubMed ID: 31144406
[TBL] [Abstract] [Full Text] [Related]
11. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating pi3k/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract] [Full Text] [Related]
12. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer.
Machado-Rugolo J; Fabro AT; Ascheri D; Farhat C; Ab'Saber AM; de Sá VK; Nagai MA; Takagaki T; Terra R; Parra ER; Capelozzi VL
Hum Pathol; 2019 Jan; 83():177-191. PubMed ID: 30218756
[TBL] [Abstract] [Full Text] [Related]
13. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
[TBL] [Abstract] [Full Text] [Related]
14. Tracking the Evolution of Non-Small-Cell lung cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract] [Full Text] [Related]
15. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Robles AI; Faus-Dáder MJ; Calleja-Hernández MÁ
Mutat Res Rev Mutat Res; 2017; 771():32-58. PubMed ID: 28342452
[TBL] [Abstract] [Full Text] [Related]
16. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract] [Full Text] [Related]
17. cancer cells increase endothelial cell tube formation and survival by activating the pi3k/Akt signalling pathway.
Cheng HW; Chen YF; Wong JM; Weng CW; Chen HY; Yu SL; Chen HW; Yuan A; Chen JJ
J Exp Clin Cancer Res; 2017 Feb; 36(1):27. PubMed ID: 28173828
[TBL] [Abstract] [Full Text] [Related]
18. SOX2 and pi3k Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during lung Squamous Cell Carcinoma Pathogenesis.
Kim BR; Van de Laar E; Cabanero M; Tarumi S; Hasenoeder S; Wang D; Virtanen C; Suzuki T; Bandarchi B; Sakashita S; Pham NA; Lee S; Keshavjee S; Waddell TK; Tsao MS; Moghal N
PLoS Biol; 2016 Nov; 14(11):e1002581. PubMed ID: 27880766
[TBL] [Abstract] [Full Text] [Related]
19. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract] [Full Text] [Related]
20. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.
Kim EY; Cho EN; Park HS; Hong JY; Lim S; Youn JP; Hwang SY; Chang YS
Cancer Biol Ther; 2016; 17(3):237-45. PubMed ID: 26785607
[TBL] [Abstract] [Full Text] [Related]
[Next]
